Cerus Corporation reiterated product revenue guidance for the full year 2024. The company expects full-year 2024 product revenue will be in the range of $172 million to $175 million. Included in this range is full-year 2024 INTERCEPT Fibrinogen Complex revenue guidance between $8 million to $10 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | +0.59% | +1.79% | -20.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.83% | 316M | |
+12.07% | 128B | |
-9.04% | 10.65B | |
+0.91% | 8.82B | |
+16.72% | 7.19B | |
+25.15% | 4.99B | |
+7.17% | 3.4B | |
-1.36% | 3.03B | |
-8.73% | 2.14B | |
-10.15% | 2B |
- Stock Market
- Equities
- CERS Stock
- News Cerus Corporation
- Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024